AlajouanineT.CastaigneP.NickJ.ContaminT.LhermitteF. (1957). Sur l'existence de signes sensitifs et sensorials au cours de la myasthénic. Rev. neurol., 96, 242
2.
AxelssonJ.ThesleffS. (1958). The ‘desensitizing’ effect of acetylcholine on the mammalian motor end-plate. Acta, physiol. scand., 43, 15
3.
BramwellB. (1892). Atlas of clinical medicine. (a)Vol. 3 p. 110 case xvi. (b) Vol. 1 p. 122. Edinburgh: University Press.
4.
BramwellE. (1938). Upon the pupil reactions—with special reference to contributions by alumni of the Edinburgh school. Edinburgh post-graduate lectures in medicine. 1, 1, Oliver and Boyd
5.
BuzzardE. F. (1905). The clinical history and postmortem examination of five cases of myasthenia gravis. Brain, 28, 438
CastlemanB.NorrisE. H. (1949). The pathology of the thymus in myasthenia gravis. Medicine (Baltimore), 28, 27
8.
ChalmersJ. N. M.BoheimerK. (1954). Pure red-cell anaemia in patients with thymic tumours. Brit. med. J., 2, 1514
9.
Churchill-DavidsonH. C.RichardsonA. T. (1952). Action of decamethonium iodide (CIO) in myasthenia gravis. J. Neurol. Neurosurg. Psychiat., 15, 129
10.
CoersC.DesmedtJ. E. (1959). Mise en évidence d'une malformation caractéristique de la jonction neuromusculaire dans la myasthénie. Acta neurol. belg., 59, 539
11.
CollierJ. (1930). Oculomotor palsies resulting from infective and toxic processes. Trans. ophthal. Soc. U.K., 50, 244
12.
ComsaJ. (1958). Influence of the thymus upon the reaction of the rat to anterior pituitary growth hormone. Nature (Lond.), 182, 728
13.
CoulonjouR.SalaunA. (1952). Sur un syndrome myasthénique fréquemment rencontré chez des chiqueurs de tabac. Sem. Hôp. Paris, 28, 3968
14.
DaleH. H.FeldbergW. (1934). Chemical transmission at motor nerve endings in voluntary muscle. J. Physiol. (Lond.), 81, 39P
15.
Denny-BrownD. (1947). Neurological conditions resulting from prolonged and severe dietary restriction. Medicine (Baltimore), 26, 41
16.
EngbaekL. (1951). Acetylcholine sensitivity in diseases of the motor system with special regard to myasthenia gravis. Electroenceph. clin. Neurophysiol., 3, 155
17.
ErbW. (1879). Zur casuistik der bulbären Lähmungen. Arch. Psychiat. Nervenkr., 9, 325
18.
GoldflamS. (1893). Ueber einen scheinbar heilbaren bulbärparalytischen Symptomencomplex mit Betheiligung der Extremitaten. Dtsch. Z. Nervenheilk., 4, 312
19.
GrobD. (1953). Course and management of myasthenia gravis. J. Amer. med. Assoc., 153, 529
20.
GrobD.JohnsR. J.HarveyA. M. (1956). Studies in neuromuscular function. IV. Stimulating and depressant effects of acetylcholine and choline in patients with myasthenia gravis, and their relationship to the defect in neuromuscular transmission. Bull. Johns Hopkins Hosp., 99, 153
21.
HarveyA. M. (1948). Some preliminary observations on the clinical course of myasthenia gravis before and after thymectomy. Bull. N.Y. Acad. Med., 24, 505
22.
HarveyA. M.ShulmanL. E.TumultyP. A.ConleyC. L.SchoenrichE. H. (1954). Systemic lupus erythematosus. Medicine (Baltimore), 33, 291
23.
HoefferP. F. A.AranowH.RowlandL. P. (1958). Myasthenia gravis and epilepsy. Arch. Neurol. Psychiat. (Chicago), 80, 10
LambieA. T.BurrowsB. A.SommersS. C. (1957). Refractory anaemia, agamma-globulinaemia, and mediastinal tumour. Amer. J. clin. Path., 27, 444
26.
LongD. A. (1955). The influence of various hormones upon immune and allergic responses of guinea-pigs to bacterial infection. Proc. roy. Soc. Med., 48, 916
27.
LowenthalA.Van SandeM. (1956). Nouvelles déterminations des fractions proteiniques dans le sérum de patients atteints d'affections musculaires. Rev. Franç. Etudes clin. biol., 1, 765
28.
MetcalfD. (1956). The thymic origin of the plasma lymphocytosis-stimulating factor. Brit. J. Cancer, 10, 442
29.
NastukW. L.StraussA. J. L.OssermanK. E. (1959). Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. Amer. J. Med., 26, 394
30.
NowellP. T.WilsonA.WilsonH. (1959). Some effects of extracts of foetal whale thymus glands. Quart. J. exp. Physiol., 44, 229
31.
OppenheimH. (1887). Ueber einen Fall von chronischer progressiver Bulbärparalyse ohne anatomischen Befund. Virchow's Arch. path. Anat., 108, 522
32.
QueridoA. (1929). On myasthenia gravis. J. nerv. ment. Dis., 69, 522
33.
RikerW. F. (1953). Some aspects of the pharmacology of neuromuscular function. Amer. J. Med., 15, 231
34.
RowlandL. P. (1955). Prostigmine-responsiveness and the diagnosis of myasthenia gravis. Neurology, 5, 612
35.
RussellD. S. (1953). Histological changes in the striped muscles in myasthenia gravis. J. Path. Bact., 65, 279
36.
SchrireJ. (1959). Progesterone metabolism in myasthenia gravis. Quart. J. Med., 28, 59
37.
SimpsonJ. A. (1958). An evaluation of thymectomy in myasthenia gravis. Brain, 81, 112
38.
SimpsonJ. A.LenmanJ. A. R. (1959). The effect of frequency of stimulation in neuromuscular disease. Electroenceph. clin. Neurophysiol., 11, 604
39.
SloanH. E. (1943). The thymus in myasthenia gravis. With observations on the normal anatomy and histology of the thymus. Surgery, 13, 154
40.
SmithersD. W. (1959). Tumours of the thyroid gland in relation to some general concepts of neoplasia. J. Fac. Radiol. (Lond.), 10, 3
41.
StrüpplerA. (1954). Experimented Untersuchungen zur Pathogenase der Myasthenie. Z. ges. exper. Med., 125, 244
42.
TaylorJ. (1958). Selected writings of John Hughlings Jackson. Vol. 2 p. 372. New York: Basie Books, Inc.
43.
WalkerM. B. (1934). Treatment of myasthenia gravis with physostigmine. Lancet, 1, 1200
44.
WeigertC. (1901). Pathologisch-anatomischer Beitrag zur Erbach' en Krankheit (Myasthenia Gravis). Neurol. Zbl., 20, 597
45.
WintrobeM. M. (1946). Clinical haematology. 2nd ed. p. 572. Philadelphia: Lea & Febiger
46.
ZaimisE. J.Churchill-DavidsonH. C.RichardsonA. T. (1952). Motor end-plate differences as a determining factor in the mode of action of neuro-muscular blocking substances. Nature (Lond.), 170, 617
47.
WilsonA.ObristA. R.WilsonH. (1953). Some effects of extracts of thymus glands removed from patients with myasthenia gravis. Lancet, 2, 368
